A desire for sustainable growth is pushing gene therapy biotechs to be strategic about manufacturing and pipelines.
Eyes are now on intismeran’s upcoming Phase II RCC readout, which they say could signal the drug’s wider potential across the solid tumour space.
The approval is based on findings from the ongoing Phase III MajesTEC-3 study involving patients with r/r MM.
The proceeds will help advance seralutinib's clinical development and potential commercialisation.
The fill-finish site will produce both autoinjectors and pre-filled syringes – serving Roche’s pipeline and portfolio.
Lilly’s drug could cut the number of injections each patient needs by 85%.
